Biopharmx Corp (NYSEAMERICAN:BPMX) To Showcase BPX-04 Rosacea Data


Biopharmx Corp (NYSEAMERICAN:BPMX) will showcase to the medical community preliminary report from the cure of rosacea utilizing its novel topical gel named BPX-04. BPX-04 marks as the firm’s latest addition to its clinical product pipeline.

The details

Biopharmx reported that BPX-04 marks as the second product advanced on the patent-pending company’s hydrophilic topical delivery system. The drug reinforces the value of the innovative delivery mechanism as company researchers evaluate other applications. As per the latest update, BioPharmX presentations will comprise a presentation on cutaneous Tolerability of a unique topical Minocycline Gel targeting Rosacea. This presentation will be done Maui Derm for Dermatologists 2018 event, January 28 – February 1. The poster will exhibit that most patients’ ratings for stinging, tightness, itching and burning were unchanged or improved.

Earlier, the company gave a presentation at the Winter Clinical Dermatology Conference that was held from January 12 to January 17 in Hawaii. The poster showcased that BPX-04 reported clinically meaningful improvements after just 4-weeks of treatment.

Anja Krammer, the President and Co-founder of Biopharmx, expressed that the promise of BPX-04 sustains to reinforce the value of their topical delivery system and its feature to offer new therapies for several indications. These presentations allow them to fulfill the demand for data on their research and communicate outcome of promising topical treatments to physicians.

Moreover, Biopharmx will be showcased in discussions of developing therapies, featuring BPX-04 for rosacea and BPX-01 for acne. The company has successfully concluded a Phase 2b study for BPX-01 and is getting set for Phase III studies. It is currently performing a pilot clinical trial for BPX-04 and is looking forward for a Phase 2 study.

BPX-041 and BPX-011 are hydrophilic topical gels having fully solubilized minocycline. After positive data from its previously reported Phase 2b dose range trial of BPX-01 in acne, the company continues with Phase III clinical trial plans for BPX-01 for the cure of inflammatory lesions of acne.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.